Abstract
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is one of the most commonly performed transplantation procedures nowadays. Despite the significant progress made in the treatment, alloHSCT is still associated with numerous complications also affecting the oral cavity. One of them is dentin hypersensitivity (DH)—a sharp, short-term pain that occurs when stimuli act on exposed dentin. Various authors point out that DH may result in a significantly lower quality of life, among other things by impeding the consumption of food as well as causing difficulties in daily oral hygiene. The aim of the study was a preliminary analysis of the incidence rate and severity of DH pain in adult patients during late period after alloHSCT. The impact of chronic graft-versus-host disease (cGvHD) and time after alloHCT were also considered. A total of 80 patients were examined. cGvHD was identified in 52 participants. The incidence rate and severity of DH pain was assessed on the basis of a questionnaire and a clinical examination. DH pain appeared a serious problem in late period after alloHSCT regardless of post-transplant time. DH primarily affected cGvHD patients. The prevention-treatment protocol for DH should be developed for this group.
Highlights
Allogeneic hematopoietic stem cell transplantation is one of the most commonly performed transplantation procedures nowadays
The aim of this study was to provide a preliminary analysis of the incidence rate and severity of dentin hypersensitivity (DH) in patients who were at least 100 days after allogeneic hematopoietic cell transplantation, taking into account the amount of time that had elapsed since the procedure as well as the possible occurrence of chronic graft-versus-host disease (cGvHD)
9 out of 10 individuals who reported severe pain in their interview simultaneously suffered from cGvHD (Table 2)
Summary
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is one of the most commonly performed transplantation procedures nowadays. In this therapy a patient receives healthy stem cells from a donor to replace their own stem cells that have been destroyed by radiation or high doses of chemotherapy (conditioning) [1]. This method is used to treat many haematological diseases, including hematologic malignancies, acquired bone marrow failure syndromes, and congenital immunodeficiency [2,3].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal of Environmental Research and Public Health
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.